Author

P. A. Goepfert

Primary ORCID profile (0000-0001-8441-5737 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

P. A. GoepfertiD1 paper · University of Alabama at Birmingham

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1

Frequent Co-Authors

A. Deshpande· 2 shared A. Loos· 2 shared C. Ye· 2 shared J. J. Kobie· 2 shared J. Woo· 2 shared J.-G. Park· 2 shared L. Martinez-Sobrido· 2 shared M. Basu· 2 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Deshpande

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Potent universal-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody

M. S. Piepenbrink, J.-G. Park, A. Deshpande, A. Loos, C. Ye, M. Basu, S. Sarkar, D. Chauvin, J. Woo, P. Lovalenti, N. B. Erdmann, P. A. Goepfert, V. L. Truong, R. A. Bowen, M. R. Walter, , J. J. Kobie

This study identifies a potent universal coronavirus neutralizing monoclonal antibody, 1249A8, effective against multiple variants and demonstrating therapeutic activity through intranasal administration.

bioRxiv · Mar 5, 2022 · PreprintImmunology

Influenza-specific effector memory B cells predict long-lived antibody responses to vaccination in humans

A. Nellore, E. Zumaquero, C. D. Scharer, R. G. King, C. M. Tipton, C. Fucile, B. Mousseau, J. E. Bradley, T. Mi, P. A. Goepfert, J. F. Kearney, J. M. Boss, T. D. Randall, I. Sanz, A. Rosenberg, F. E. Lund

The paper identifies T-bethi Bmem cells as predictors of long-lived antibody responses to influenza vaccination in humans.

bioRxiv · Feb 18, 2021 · PreprintImmunology

Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters

M. S. Piepenbrink, J.-G. Park, F. Oladunni, A. Deshpande, M. Basu, S. Sarkar, A. Loos, J. Woo, P. Lovalenti, D. Sloan, C. Ye, K. Chiem, N. B. Erdmann, P. A. Goepfert, V. L. Truong, , J. J. Kobie

This study evaluates an inhaled monoclonal antibody against SARS-CoV-2 in hamsters, showing reduced viral burden and lung pathology with low-dose inhalation.

bioRxiv · Oct 14, 2020Immunology